Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 15, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing increases in their personal holdings of the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The material change reported is an increase in share ownership by specific individuals following the re-investment of dividends paid on October 11, 2007. The transactions occurred at a price of GBP 13.05 per ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Increase in ordinary share holdings via dividend re-investment.
- Transaction Price: GBP 13.05 per share.
- Dividend Date: October 11, 2007.
- Notified Parties: Mr J S Heslop, Mrs P A Heslop, Mr R Bondy, Mr D Learmouth, Dr D Pulman, Mrs C Pulman, Mr A P Witty, and Mrs C M Witty.
- Notification Date: October 15, 2007.